Evaluating the decisions of glioma patients regarding clinical trial participation: a retrospective single provider review

Grant W. Jirka, Karl Stessy M. Bisselou, Lynette M. Smith, Nicole Shonka

Research output: Contribution to journalArticle

Abstract

Clinical trial accrual is vital to advancing care. A single study elucidated demographic data correlating with glioma patients’ clinical trial enrollment. However, it did not investigate the underlying decision-making process for non-participation. In this study, we seek to understand this key aspect of patient accrual. All notes for glioma patients seen by a single neuro-oncologist from July 2010 to May 2017 were examined for mention of clinical trial offerings. When a trial was declined, the patient’s reasoning was recorded along with the following: diagnosis, KPS, extent of resection, age, gender, race, marital status, income group, religion, trial offered at initial visit versus subsequent, and distance from trial site. Of 279 consecutive glioma patients, 88 were eligible for and offered a clinical trial. Fifty-seven accepted (65%), and 31 (35%) declined participation (Fig. 1). Of those offered a clinical trial, patients with glioblastoma (GBM) were significantly more likely to accept (44 out of 57 (77%) vs. 13 out of 57 (23%), p =0.03). After we adjusted for gender and travel distance, GBM was the only significant predictor of clinical trial acceptance, with an odds ratio of 3.18 (95% CI 1.17, 8.61, p =0.02). Reasons cited for non-participation included: travel distance (39%), lack of interest (39%), visit frequency (16%), and fear of randomization (6%). This study clarified for the first time individual glioma patient rationale for non-participation and potential areas for improving enrollment. Allowing off-site treatment centers or telemedicine visits may entice rural patients to participate. Visit frequency should be carefully considered and minimized whenever possible. Further prospective study of rationale for non-participation may improve enrollment over time.

Original languageEnglish (US)
Article number34
JournalMedical Oncology
Volume36
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Glioma
Clinical Trials
Glioblastoma
Telemedicine
Marital Status
Religion
Random Allocation
Fear
Decision Making
Odds Ratio
Demography
Prospective Studies

Keywords

  • Accrual
  • Clinical trial
  • Evaluating decisions
  • Glioma
  • Non-participation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Evaluating the decisions of glioma patients regarding clinical trial participation : a retrospective single provider review. / Jirka, Grant W.; Bisselou, Karl Stessy M.; Smith, Lynette M.; Shonka, Nicole.

In: Medical Oncology, Vol. 36, No. 4, 34, 01.04.2019.

Research output: Contribution to journalArticle

@article{66a7d8637dd54604b8f48ef0ca99e476,
title = "Evaluating the decisions of glioma patients regarding clinical trial participation: a retrospective single provider review",
abstract = "Clinical trial accrual is vital to advancing care. A single study elucidated demographic data correlating with glioma patients’ clinical trial enrollment. However, it did not investigate the underlying decision-making process for non-participation. In this study, we seek to understand this key aspect of patient accrual. All notes for glioma patients seen by a single neuro-oncologist from July 2010 to May 2017 were examined for mention of clinical trial offerings. When a trial was declined, the patient’s reasoning was recorded along with the following: diagnosis, KPS, extent of resection, age, gender, race, marital status, income group, religion, trial offered at initial visit versus subsequent, and distance from trial site. Of 279 consecutive glioma patients, 88 were eligible for and offered a clinical trial. Fifty-seven accepted (65{\%}), and 31 (35{\%}) declined participation (Fig. 1). Of those offered a clinical trial, patients with glioblastoma (GBM) were significantly more likely to accept (44 out of 57 (77{\%}) vs. 13 out of 57 (23{\%}), p =0.03). After we adjusted for gender and travel distance, GBM was the only significant predictor of clinical trial acceptance, with an odds ratio of 3.18 (95{\%} CI 1.17, 8.61, p =0.02). Reasons cited for non-participation included: travel distance (39{\%}), lack of interest (39{\%}), visit frequency (16{\%}), and fear of randomization (6{\%}). This study clarified for the first time individual glioma patient rationale for non-participation and potential areas for improving enrollment. Allowing off-site treatment centers or telemedicine visits may entice rural patients to participate. Visit frequency should be carefully considered and minimized whenever possible. Further prospective study of rationale for non-participation may improve enrollment over time.",
keywords = "Accrual, Clinical trial, Evaluating decisions, Glioma, Non-participation",
author = "Jirka, {Grant W.} and Bisselou, {Karl Stessy M.} and Smith, {Lynette M.} and Nicole Shonka",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s12032-019-1259-z",
language = "English (US)",
volume = "36",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Evaluating the decisions of glioma patients regarding clinical trial participation

T2 - a retrospective single provider review

AU - Jirka, Grant W.

AU - Bisselou, Karl Stessy M.

AU - Smith, Lynette M.

AU - Shonka, Nicole

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Clinical trial accrual is vital to advancing care. A single study elucidated demographic data correlating with glioma patients’ clinical trial enrollment. However, it did not investigate the underlying decision-making process for non-participation. In this study, we seek to understand this key aspect of patient accrual. All notes for glioma patients seen by a single neuro-oncologist from July 2010 to May 2017 were examined for mention of clinical trial offerings. When a trial was declined, the patient’s reasoning was recorded along with the following: diagnosis, KPS, extent of resection, age, gender, race, marital status, income group, religion, trial offered at initial visit versus subsequent, and distance from trial site. Of 279 consecutive glioma patients, 88 were eligible for and offered a clinical trial. Fifty-seven accepted (65%), and 31 (35%) declined participation (Fig. 1). Of those offered a clinical trial, patients with glioblastoma (GBM) were significantly more likely to accept (44 out of 57 (77%) vs. 13 out of 57 (23%), p =0.03). After we adjusted for gender and travel distance, GBM was the only significant predictor of clinical trial acceptance, with an odds ratio of 3.18 (95% CI 1.17, 8.61, p =0.02). Reasons cited for non-participation included: travel distance (39%), lack of interest (39%), visit frequency (16%), and fear of randomization (6%). This study clarified for the first time individual glioma patient rationale for non-participation and potential areas for improving enrollment. Allowing off-site treatment centers or telemedicine visits may entice rural patients to participate. Visit frequency should be carefully considered and minimized whenever possible. Further prospective study of rationale for non-participation may improve enrollment over time.

AB - Clinical trial accrual is vital to advancing care. A single study elucidated demographic data correlating with glioma patients’ clinical trial enrollment. However, it did not investigate the underlying decision-making process for non-participation. In this study, we seek to understand this key aspect of patient accrual. All notes for glioma patients seen by a single neuro-oncologist from July 2010 to May 2017 were examined for mention of clinical trial offerings. When a trial was declined, the patient’s reasoning was recorded along with the following: diagnosis, KPS, extent of resection, age, gender, race, marital status, income group, religion, trial offered at initial visit versus subsequent, and distance from trial site. Of 279 consecutive glioma patients, 88 were eligible for and offered a clinical trial. Fifty-seven accepted (65%), and 31 (35%) declined participation (Fig. 1). Of those offered a clinical trial, patients with glioblastoma (GBM) were significantly more likely to accept (44 out of 57 (77%) vs. 13 out of 57 (23%), p =0.03). After we adjusted for gender and travel distance, GBM was the only significant predictor of clinical trial acceptance, with an odds ratio of 3.18 (95% CI 1.17, 8.61, p =0.02). Reasons cited for non-participation included: travel distance (39%), lack of interest (39%), visit frequency (16%), and fear of randomization (6%). This study clarified for the first time individual glioma patient rationale for non-participation and potential areas for improving enrollment. Allowing off-site treatment centers or telemedicine visits may entice rural patients to participate. Visit frequency should be carefully considered and minimized whenever possible. Further prospective study of rationale for non-participation may improve enrollment over time.

KW - Accrual

KW - Clinical trial

KW - Evaluating decisions

KW - Glioma

KW - Non-participation

UR - http://www.scopus.com/inward/record.url?scp=85062586421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062586421&partnerID=8YFLogxK

U2 - 10.1007/s12032-019-1259-z

DO - 10.1007/s12032-019-1259-z

M3 - Article

C2 - 30840157

AN - SCOPUS:85062586421

VL - 36

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - 4

M1 - 34

ER -